Landos Biopharma Executives
LABPDelisted Stock | USD 4.02 0.15 3.60% |
Landos Biopharma employs about 19 people. The company is managed by 7 executives with a total tenure of roughly 45 years, averaging almost 6.0 years of service per executive, having 2.71 employees per reported executive. Discussion of Landos Biopharma's management performance can provide insight into the enterprise performance.
Landos |
Landos Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3938) % which means that it has lost $0.3938 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7067) %, meaning that it created substantial loss on money invested by shareholders. Landos Biopharma's management efficiency ratios could be used to measure how well Landos Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Landos Biopharma Workforce Comparison
Landos Biopharma is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 194. Landos Biopharma holds roughly 19.0 in number of employees claiming about 10% of equities under Health Care industry.
Landos Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Landos Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Landos Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Landos Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gregory Oakes over six months ago Acquisition by Gregory Oakes of 1677251 shares of Landos Biopharma at 0.79 subject to Rule 16b-3 | ||
Bassaganya-riera Josep over six months ago Disposition of 786299 shares by Bassaganya-riera Josep of Landos Biopharma at 1888814.77 subject to Rule 16b-3 | ||
Xontogeny, Llc over six months ago Acquisition by Xontogeny, Llc of 10709 shares of Landos Biopharma at 14.18 subject to Rule 16b-3 | ||
Gregory Oakes over six months ago Acquisition by Gregory Oakes of 54454 shares of Landos Biopharma subject to Rule 16b-3 | ||
Mayleben Timothy M over a year ago Acquisition by Mayleben Timothy M of 18000 shares of Landos Biopharma subject to Rule 16b-3 | ||
Batycky Alka over a year ago Acquisition by Batycky Alka of 3600 shares of Landos Biopharma subject to Rule 16b-3 | ||
Callori Fred over a year ago Acquisition by Callori Fred of 18000 shares of Landos Biopharma subject to Rule 16b-3 | ||
Bassaganyariera Josep over a year ago Sale by Bassaganyariera Josep of 3470736 shares of Landos Biopharma |
Landos Biopharma Notable Stakeholders
A Landos Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Landos Biopharma often face trade-offs trying to please all of them. Landos Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Landos Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gregory Oakes | CEO President | Profile | |
Rebecca Mosig | Executive Development | Profile | |
Patrick Truesdell | Principal Officer | Profile | |
Timothy MBA | Principal Director | Profile | |
Jennifer Creel | Interim Officer | Profile | |
Josep DVM | Advisor | Profile | |
Fabio MD | Executive Officer | Profile |
About Landos Biopharma Management Performance
The success or failure of an entity such as Landos Biopharma often depends on how effective the management is. Landos Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Landos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Landos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia. Landos Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Landos Biopharma Workforce Analysis
Traditionally, organizations such as Landos Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Landos Biopharma within its industry.Landos Biopharma Manpower Efficiency
Return on Landos Biopharma Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.2M | |
Net Loss Per Executive | 3.1M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 4.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |